MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
22.70
-0.52
-2.24%
After Hours: 22.70 0 0.00% 16:10 02/10 EST
OPEN
23.14
PREV CLOSE
23.22
HIGH
23.26
LOW
22.66
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
28.35
52 WEEK LOW
13.40
MARKET CAP
3.84B
P/E (TTM)
14.62
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACAD last week (0202-0206)?
Weekly Report · 1d ago
ACADIA Pharmaceuticals Is Maintained at Perform by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23
Benzinga · 4d ago
Acadia Pharmaceuticals price target raised to $23 from $21 at Oppenheimer
TipRanks · 4d ago
BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts
Reuters · 4d ago
BUZZ-Jefferies cuts PT, earnings forecasts on Australia's Neuren after setback for Rett drug in Europe
Reuters · 5d ago
ASX 200 healthcare stock sinks 9% on FDA update
The Motley Fool · 5d ago
ACADIA Pharmaceuticals Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results
Reuters · 6d ago
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.